The Procurement Entities HUS and ISLAB asked for tenders for the subcontracting service of gene expression based tumor profiling test for breast cancer. The test was intended to be used in risk classification of patients with hormone receptor-positive (ER+), HER2 (human epidermal growth factor receptor 2) negative breast cancer, when considering the initiation of chemotherapy. The test should provide both a predictive and prognostic tool to estimate a patient’s risk of distant breast-cancer recurrence. The tumor profiling test must demonstrably improve the risk classification of patients and identify those patients who will benefit the most from chemotherapy.